Human to pet in just one step.

Our proprietary PETization platform enables the rapid translation of therapeutic monoclonal antibodies (mAbs) between species.

Our mAbs are uniquely designed to be accepted by a patient's immune system as "native," a property we refer to as "100% species-specificity."

Our most advanced therapies in development are focused on treatments within four general areas: chronic pain, chronic inflammation, allergy, and immuno-oncology (cancer).

We believe biologic therapies as a class offer significant advantages over current treatments in these areas, including: safety, longer duration of action (and therefore less frequent dosing), and injectability.

Our team of scientists and veterinarians are working to investigate further opportunities for new biologic therapies.

A diverse team of experts who are passionate about animal health.

Meet our team

Nexvet on tour

7-9 March 2016

Cowen Annual Health Care Conference, Boston, MA, U.S.

10-12 May 2016

Bank of America Merrill Lynch 2016 Health Care Conference, Las Vegas, U.S.

8–11 June 2016

American College of Veterinary Internal Medicine Forum, CO, U.S.

22-25 June 2016

FECAVA Eurocongress, Vienna, Austria

27–30 July 2016

Veterinary Pain Short Course, San Diego, CA, U.S.

17–19 August 2016

International Veterinary Immunology Symposium, Gold Coast, Australia

26-30 September 2016

World Congress on Pain, Yokohama, Japan

Keep up with the transformation

Hear more — follow us on social media, browse extra content, and subscribe to our newsletter here.



31 May 2016

RT @dccatwriter: #arthritis drug for cats shows promise, firm says @Nexvet @ACVIM @CatVets

Register for Our Newsletter

Nexvet Biopharma

Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98
P: + 353 5793 24522 

Level 8, 31 Queen Street
Melbourne 3000
P: +61 (3) 9610 4400

United States
275 Post Street
4th Floor
San Francisco, CA 94108


Get in Touch